CS
TVTX icon

Candriam SCA’s Travere Therapeutics TVTX Stock Holding History

Candriam SCA’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Sell
369,995
-98,561
-21% -$2.95M 0.06% 266
2025
Q4 		$17.9M Sell
468,556
-44,125
-9% -$1.43M 0.09% 200
2025
Q3 		$12.3M Hold
512,681
– – 0.06% 247
2025
Q2 		$7.59M Sell
512,681
-21,391
-4% -$355K 0.04% 293
2025
Q1 		$9.57M Buy
+534,072
New +$10.8M 0.06% 243

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA's TVTX Position: Q1 2026 in Review

Candriam SCA reduced its Travere Therapeutics (TVTX) stake by 21% in Q1 2026, selling an estimated $2.95M and leaving 369,995 shares worth $11M. The position accounts for 0.06% of the portfolio, ranked #266.

Candriam SCA first reported a position in TVTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $17.9M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Candriam SCA held 369,995 shares of Travere Therapeutics worth $11M as of Q1 2026.
  • Candriam SCA sold 98,561 Travere Therapeutics shares in Q1 2026, an estimated $2.95M.
  • Travere Therapeutics made up 0.06% of Candriam SCA's portfolio in Q1 2026, its #266 holding.
  • Candriam SCA first reported a position in Travere Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Candriam SCA's Travere Therapeutics position peaked at $17.9M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.